65,437 trials
Diabetic Neuropathies · Depressive Disorder, Major
Primary: Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12 — -1.4; -2.2 Scores on a scale — p=< 0.0001
Dry Eye Syndromes
Primary: Mean Frequency of Eye Drop Use Over 1 Week — 1.76; 1.66 Use per day
Dry Eye Syndromes
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2 — 56.06; 54.292; -27.048; -28.303 Scores on a Scale
Prostatic Hyperplasia
Primary: Number of Participants With Adverse Events (AEs) — 14 Participants
Nephrosis · Focal Lipoid Glomerulosclerosis
Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074
Other Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), 24 Months/Endpoint, ITT Population. — 1.22; 5.75 Percent Change — p=<0.0001
HIV Infections
Primary: The Percentage of Patients Who Maintain a Viral Load < 50 Copies/ml After Being Switched From Enfuvirtide to Raltegravir — 86 percentage
Infant, Preterm
Primary: Peak Inspiratory Pressure — 13.45; 12.45 cmH2O — p=0.043
Type 2 Diabetes Mellitus
Primary: Subjects Experiencing Serious Adverse Events — 176; 98 participants — p=<0.05
Overactive Bladder
Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07
Pulmonary Disease, Chronic Obstructive
Primary: Post-index Period COPD-related, Unadjusted Costs — 688; 867; 55; 52 United States (US) dollars
Rhinitis, Allergic, Perennial and/or Seasonal
Primary: Ratio of Serum Cortisol Area Under Curve [AUC(0-24 hr)] at the End of Treatment to Baseline — 0.938; 0.898 Ratio
Ocular Hypertension · Glaucoma
Primary: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12 — 21.90; 22.16; -5.64; -4.89 millimeters of mercury (mmHg)
Bacterial Conjunctivitis
Primary: Number of Participants Who Achieved Clinical Resolution at Visit 3 — 127; 123 Participants
Diabetic Neuropathies · Polyneuropathies
Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale